5-[4-(2-(2-pyrimidinylamino)-ethoxy)benzyl]-2,4-thiazolidinedione | 122320-66-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-[4-(2-(2-pyrimidinylamino)-ethoxy)benzyl]-2,4-thiazolidinedione
• 英文别名: 5-{4-[2-(2-pyrimidinylamino)ethoxy]benzyl}thiazolidine-2,4-dione；5-(4-(2-(2-Pyrimidinylamino)ethoxy)benzyl]-2,4-thiazolidinedione；5-[[4-[2-(pyrimidin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• CAS: 122320-66-5
• 化学式: C₁₆H₁₆N₄O₃S
• 分子量: 344.394
• InChiKey: BZYJVHSYHURRND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1,4-二氧六环 、 5-[4-(2-(2-pyrimidinylamino)-ethoxy)benzyl]-2,4-thiazolidinedione 以 二氯甲烷 、 水 、 乙酸酐 为溶剂， 生成 5-(4-[2-(N-Acetyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione
  参考文献：
  名称：

  Compounds

  摘要：

  式(I)的化合物：##STR1##或其互变异构体，或其药学上可接受的盐，或其药学上可接受的溶剂化合物，其中：A.sup.1代表取代或未取代的芳香杂环基团；R.sup.1代表氢原子，烷基团，酰基团，芳基烷基团，其中芳基部分可以是取代或未取代的，或取代或未取代的芳基团；R.sup.2和R.sup.3各自代表氢，或R.sup.2和R.sup.3一起代表键；A.sup.2代表总共最多具有五个取代基的苯环；n代表范围在2到6之间的整数；含有这种化合物的药物组合物以及这种化合物和组合物在医学中的用途。

  公开号：

  US05194443A1
• 作为产物：
  描述：

  2-(2-嘧啶基氨基)乙醇 在 palladium on activated charcoal 氢气 、 哌啶乙酸盐 、 sodium hydride 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 18.0~25.0 ℃ 、101.33 kPa 条件下， 反应 20.0h， 生成 5-[4-(2-(2-pyrimidinylamino)-ethoxy)benzyl]-2,4-thiazolidinedione
  参考文献：
  名称：

  [[.omega.-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents

  摘要：

  A series of [(ureidoethoxy)benzyl]-2,4-thiazolidinediones and [[(heterocyclylamino)alkoxy]-benzyl]-2,4-thiazolidinediones was synthesized from the corresponding aldehydes. Compounds from the urea series, exemplified by 16, showed antihyperglycemic potency comparable with known agents of the type such as pioglitazone and troglitazone (CS-045). The benzoxazole 49, a cyclic analogue of 16, was a very potent enhancer of insulin sensitivity, and by modification of the aromatic heterocycle, an aminopyridine, 37, was identified as a lead compound from SAR studies. Evaluation of antihyperglycemic activity together with effects on blood hemoglobin content, to determine the therapeutic index, was performed in 8-day repeat administration studies in genetically obese C57 Bl/6 ob/ob mice. From these studies, BRL 49653 (37) has been selected, on the basis of antihyperglycemic potency combined with enhanced selectivity against reductions in blood hemoglobin content, for further evaluation.

  DOI：

  10.1021/jm00049a017

文献信息

• Substituted thiazolidinedione derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0842925A1

  公开（公告）日：1998-05-20

  Compounds of formula (I): or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A1 represents a substituted or unsubstituted aromatic heterocyclyl group; R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R2 and R3 each represent hydrogen, or R2 and R3 together represent a bond; A2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.

  式(I)的化合物，或其互变异构体，或其药学上可接受的盐，或其药学上可接受的溶剂化物，其中：A1代表取代或未取代的芳香杂环基团；R1代表氢原子、烷基团、酰基团、芳基烷基团，其中芳基部分可以是取代或未取代的，或取代或未取代的芳基基团；R2和R3各自代表氢，或R2和R3一起代表键；A2代表苯环，最多具有五个取代基；n代表在2到6范围内的整数；包含这种化合物的药学组合物以及这种化合物和组合物在医学上的用途。
• Compounds for treating eating disorders in which blood glucose levels
  申请人：Beecham Group p.l.c.

  公开号：US05646169A1

  公开（公告）日：1997-07-08

  A method is provided for the treatment and/or prophylaxis of eating disorders in a human or non-human mammal, which comprises administering to a human or non-human mammal in need thereof, an effective, non-toxic amount of a compound of formula (I): ##STR1## or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, in which A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6.

  本发明提供了一种用于治疗和/或预防人类或非人类哺乳动物的进食障碍的方法，该方法包括向需要该治疗的人类或非人类哺乳动物中给予有效的、非毒性的化合物(I)的量：##STR1## 或其互变异构体和/或药学上可接受的盐和/或药学上可接受的溶剂，其中A.sup.1代表取代或未取代的芳香杂环基；R.sup.1代表氢原子、烷基、酰基、芳基烷基，其中芳香基团可以是取代或未取代的，或取代或未取代的芳基基团；R.sup.2和R.sup.3分别代表氢，或R.sup.2和R.sup.3一起代表键；A.sup.2代表苯环，其总共有多达五个取代基；n代表在2到6的整数范围内。
• NOVEL COMPOUNDS
  申请人：Beecham Group p.1.c.

  公开号：US20020049240A1

  公开（公告）日：2002-04-25

  Compounds of formula (I): 1 or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A 1 represents a substituted or unsubstituted aromatic heterocyclyl group; R 1 represents a hydrocarbon atom, an alkyl group, an acyl grup, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R 2 and R 3 each represent hydrogen, or R 2 and R 3 together represent a bond; A 2 represents a benzene ring having a total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.

  化合物的式子（I）：其中1或其互变异构体，或其药学上可接受的盐，或其药学上可接受的溶剂盐，其中：A1代表取代或未取代的芳香杂环基团；R1代表碳氢原子，烷基，酰基，苯基烷基，其中芳基部分可能被取代或未取代，或者是取代或未取代的芳基基团；R2和R3分别代表氢，或者R2和R3一起代表一个键；A2代表苯环，具有最多五个取代基；n代表在2到6之间的整数；包含这种化合物的药物组合物以及这种化合物和组合物在医学上的用途。
• 2,4-thiazolidinediones
  申请人：Beecham Group p.l.c.

  公开号：US05260445A1

  公开（公告）日：1993-11-09

  Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.

  化合物的式子(I): ## STR1 ## 或其互变异构体，或其药学上可接受的盐，或其药学上可接受的溶剂，其中：A.sup.1代表取代或未取代的芳香杂环基团；R.sup.1代表氢原子，烷基团，酰基团，芳基烷基团，其中芳基部分可能取代或未取代，或取代或未取代的芳基基团；R.sup.2和R.sup.3各代表氢，或R.sup.2和R.sup.3一起代表键；A.sup.2代表苯环，其总共有多达五个取代基；n代表在2到6之间的整数；包含这种化合物的药物组合物以及这种化合物和组合物在医学上的应用。
• Method for treatment of atherosclerosis
  申请人：Beecham Group p.l.c.

  公开号：US05521201A1

  公开（公告）日：1996-05-28

  A method is provided for the treatment and/or prophylaxis of cardiovascular diseases in a human or non-human mammal, which comprises administering to a human or non-human mammal in need thereof, an effective, non-toxic amount of a compound of formula (I): ##STR1## or a tautomeric form thereof and/or a pharmaceuticlaly acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, in which A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6.

  本发明提供了一种治疗和/或预防人或非人哺乳动物心血管疾病的方法，该方法包括向需要该方法的人或非人哺乳动物中给予有效的、非毒性的化合物(I)的量：##STR1## 或其互变异构体和/或其药学上可接受的盐和/或其药学上可接受的溶剂，其中，A.sup.1代表取代或未取代的芳香杂环基；R.sup.1代表氢原子、烷基、酰基、芳基烷基，其中芳基部分可以被取代或未取代，或取代或未取代的芳基基团；R.sup.2和R.sup.3各自代表氢，或R.sup.2和R.sup.3一起代表键；A.sup.2代表总共有多达五个取代基的苯环；n代表在2到6的整数范围内。